CIA
IDXX icon

Concurrent Investment Advisors’s Idexx Laboratories IDXX Stock Holding History

Concurrent Investment Advisors’s Portfolio IDXX Stock Details IDXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$631K Buy
1,199
+292
+32% +$164K 0.01% 1272
2026
Q1 		$509K Sell
907
-87
-9% -$55.8K 0.01% 1207
2025
Q4 		$673K Sell
994
-642
-39% -$437K 0.01% 1015
2025
Q3 		$1.05M Buy
1,636
+147
+10% +$89.2K 0.02% 644
2025
Q2 		$799K Buy
1,489
+119
+9% +$56.9K 0.02% 673
2025
Q1 		$575K Buy
1,370
+509
+59% +$221K 0.01% 707
2024
Q4 		$356K Buy
861
+231
+37% +$101K 0.01% 763
2024
Q3 		$318K Buy
630
+28
+5% +$13.6K 0.01% 759
2024
Q2 		$293K Buy
602
+156
+35% +$78.3K 0.01% 744
2024
Q1 		$241K Buy
446
+48
+12% +$26.2K 0.01% 738
2023
Q4 		$221K Buy
+398
New +$187K 0.01% 740

Other funds holding IDXX

MBI
Montrusco Bolton Investments Montreal, Quebec, Canada $6.46B AUM 26.7% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.55B AUM 11.62% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Robeco Institutional Asset Management
Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
RG
Rathbones Group Liverpool, United Kingdom $27.1B AUM 20.2% 1-Year Est. Return
LWCFA
Loring Wolcott & Coolidge Fiduciary Advisors Boston, Massachusetts $10.3B AUM 3.26% 1-Year Est. Return

Concurrent Investment Advisors's IDXX Position: Q2 2026 in Review

Concurrent Investment Advisors increased its Idexx Laboratories (IDXX) stake by 32% in Q2 2026, buying an estimated $164K and bringing the position to 1,199 shares worth $631K. The position accounts for 0.01% of the portfolio, ranked #1272.

Concurrent Investment Advisors first reported a position in IDXX in Q4 2023 and has held it in 11 quarters since. The position peaked at $1.05M in Q3 2025. 509 funds tracked by Wall St. Rank hold IDXX as of Q2 2026.

  • Concurrent Investment Advisors held 1,199 shares of Idexx Laboratories worth $631K as of Q2 2026.
  • Concurrent Investment Advisors bought 292 Idexx Laboratories shares in Q2 2026, an estimated $164K.
  • Idexx Laboratories made up 0.01% of Concurrent Investment Advisors's portfolio in Q2 2026, its #1272 holding.
  • Concurrent Investment Advisors first reported a position in Idexx Laboratories in Q4 2023 and has held it in 11 quarters since.
  • Concurrent Investment Advisors's Idexx Laboratories position peaked at $1.05M in Q3 2025.
  • 509 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2026.

Based on Concurrent Investment Advisors's 13F filing for Q2 2026, filed 27 Jul 2026.